Pharma Companies Need To ‘Think A Little Bigger’ To Avoid Government Enforcement Actions
Executive Summary
Industry executives note lessons learned from ‘fascinating’ approaches DOJ and states have taken in recent settlements, from restrictions on Novartis speaker programs to targeting McKinsey’s marketing advice. Chart includes details of 18 settlements since January 2020.